JOP20200327A1 - مركبات سيانوتريازول واستخداماتها - Google Patents

مركبات سيانوتريازول واستخداماتها

Info

Publication number
JOP20200327A1
JOP20200327A1 JOP/2020/0327A JOP20200327A JOP20200327A1 JO P20200327 A1 JOP20200327 A1 JO P20200327A1 JO P20200327 A JOP20200327 A JO P20200327A JO P20200327 A1 JOP20200327 A1 JO P20200327A1
Authority
JO
Jordan
Prior art keywords
compounds
present
cyanotriazole
cyanotriazole compounds
compositions
Prior art date
Application number
JOP/2020/0327A
Other languages
English (en)
Inventor
Srinivasa P S Rao
Shuyi Pearly Ng
Jan Jiricek
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of JOP20200327A1 publication Critical patent/JOP20200327A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يوفر الاختراع الحالي مركب من الصيغة (I) أو ملح مقبول صيدلانياً منه: حيث يكون R1، R2، R3، وR4 كما تحدد هنا. يوفر الاختراع الحالي أيضاً استخدامات علاجية لهذه المركبات، على سبيل المثال ضد المثقبيات الأفريقية البشرية؛ تركيبات صيدلانية تشتمل على هذه المركبات، وتركيبات تشتمل على هذه المركبات مع عامل مساعد علاجي.
JOP/2020/0327A 2018-06-19 2019-06-18 مركبات سيانوتريازول واستخداماتها JOP20200327A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862687045P 2018-06-19 2018-06-19
PCT/IB2019/055123 WO2019244049A1 (en) 2018-06-19 2019-06-18 Cyanotriazole compounds and uses thereof

Publications (1)

Publication Number Publication Date
JOP20200327A1 true JOP20200327A1 (ar) 2020-12-15

Family

ID=67841115

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0327A JOP20200327A1 (ar) 2018-06-19 2019-06-18 مركبات سيانوتريازول واستخداماتها

Country Status (21)

Country Link
US (1) US20220106296A1 (ar)
EP (1) EP3810598A1 (ar)
JP (1) JP2021528397A (ar)
KR (1) KR20210022646A (ar)
CN (1) CN112313217A (ar)
AU (1) AU2019291490B2 (ar)
BR (1) BR112020025538A2 (ar)
CA (1) CA3100954A1 (ar)
CL (1) CL2020003252A1 (ar)
CR (1) CR20200619A (ar)
CU (1) CU20200102A7 (ar)
EA (1) EA202190064A1 (ar)
EC (1) ECSP20080991A (ar)
IL (1) IL279483A (ar)
JO (1) JOP20200327A1 (ar)
MA (1) MA52977A (ar)
MX (1) MX2020013729A (ar)
PE (1) PE20210780A1 (ar)
PH (1) PH12020552186A1 (ar)
SG (1) SG11202012628XA (ar)
WO (1) WO2019244049A1 (ar)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115181060B (zh) * 2022-08-19 2024-03-19 江苏禾裕泰化学有限公司 一种生产2-氨基-3-氯-5-三氟甲基吡啶的清洁生产工艺
CN116284772B (zh) * 2023-02-09 2024-02-27 四川大学 一种联吡啶三唑共价有机聚合物及其制备方法和应用
CN116836111A (zh) * 2023-09-01 2023-10-03 峰成医药科技(天津)有限公司 一种氟代吡啶的连续化合成方法
WO2025163522A1 (en) * 2024-01-31 2025-08-07 Novartis Ag Cyanotriazole compounds and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US8642774B2 (en) * 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
DK2790705T3 (en) * 2011-12-15 2018-03-12 Novartis Ag Use of inhibitors of the activity or function of PI3K
EP3237400A1 (en) * 2014-12-22 2017-11-01 GlaxoSmithKline Intellectual Property Management Limited Thiotriazole compound and its use in parasitic protozoal infections

Also Published As

Publication number Publication date
CR20200619A (es) 2021-01-21
EA202190064A1 (ru) 2021-03-29
EP3810598A1 (en) 2021-04-28
MX2020013729A (es) 2021-05-12
PE20210780A1 (es) 2021-04-21
BR112020025538A2 (pt) 2021-03-16
AU2019291490A1 (en) 2021-02-04
CU20200102A7 (es) 2021-08-06
KR20210022646A (ko) 2021-03-03
JP2021528397A (ja) 2021-10-21
WO2019244049A1 (en) 2019-12-26
AU2019291490B2 (en) 2022-02-10
ECSP20080991A (es) 2021-02-26
CL2020003252A1 (es) 2021-07-09
IL279483A (en) 2021-01-31
CN112313217A (zh) 2021-02-02
US20220106296A1 (en) 2022-04-07
PH12020552186A1 (en) 2021-06-07
MA52977A (fr) 2021-04-28
SG11202012628XA (en) 2021-01-28
CA3100954A1 (en) 2019-12-26

Similar Documents

Publication Publication Date Title
ZA202206923B (en) New methylquinazolinone derivatives
PH12020551821A1 (en) Novel compounds
SA520411524B1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
WO2020106647A3 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
EP4360707A3 (en) Compositions for treating spinal muscular atrophy
PH12022551226A1 (en) Pyrrolotriazine compounds acting as mnk inhibitor
PH12021551257A1 (en) Cyclic pantetheine derivatives and uses thereof
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MY194116A (en) Pharmaceutical compounds
PH12021552513A1 (en) Pyrrole compounds
MY199779A (en) Pyrrolopyrimidine compound and use thereof
PH12022551241A1 (en) Egfr inhibitors
CR20210181A (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
PH12020551341A1 (en) 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
MX379704B (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
PH12021552953A1 (en) Tricyclic compounds
PH12019502170A1 (en) Combination of isoindolinone derivatives with sgi-110
MX2022006104A (es) Composicion farmaceutica oral que comprende compuesto de carbamato y metodo de preparacion para la misma.
MX2021009717A (es) Sulfonamidas biciclicas.
MX2019014321A (es) Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias.
JOP20220082A1 (ar) مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
PH12022550860A1 (en) 5-oxa-2-azaspiro[3.4]octane derivatives as m4 agonists
NZ764463A (en) Heterocyclic compound and application thereof in medicine
MY208423A (en) Composition of aminopyran derivative